



Simeprevir and Sofosbuvir for treatment chronic infection with hepatitis C virus.

Villalobos Torres, L.; Asensi Díez, R.; Muñoz Castillo, I.

Hospital Regional Universitario de Málaga



To evaluate the effectiveness of the combination siemprevir plus sofosbuvir in HCV patients.


Material and methods

Retrospective and observational study between October 2014 and March 2015. Inclusion Criteria: Patients with HCV infection treated with SOF+SMV during the study. Exclusion Criteria: Patients with no data were available. Variables: Demographics: Age and sex. Clinical: Basal viral load (VL), rapid virological response (HCV RNA undetectable 4 weeks after the start of treatment), VL week 12 and sustained virological response at week 12 (SVR12) defined as HCV RNA titres lower than 15 IU/mL. Metavir scores: F0-F4. Liver transplant, HCV genotype, HIV co-infection, previous treatments for HCV.

Data source: Data were collected from medical records of patients

Naive:

33.82%



Previous treatment <u>Treated:</u> with Peq- 66.17%




68 patients were included (42 male), with an average age of 55.7±9.9 years.

Rapid virological response (week 4), was achieved in 85.29% of patients. At week 12, 98.53% of the patients had HCV RNA undetectable. Only one patient had a VL of 266 IU/mL.

SVR12 was achieved in 88.24% (60/68) of the patients. The rapid virological response and SVR12 rates in our study are consistent with those obtained in the COSMOS study (rapid virological response 81% and SVR12 93% in the ITT population in both treatments cohorts).

with i eg	00.1770	00.0270
IFN+Ribavirine	(45/68)	(23/68)
HIV-1 Co-infected	<u>Co-infected:</u> 19.12% (13/68)	<u>Only HCV:</u> 80.88% (55/68)
Liver transplant	Transplanted: 17.65% (12/68)	<u>Not</u> <u>transplanted</u> : 82.35% (56/68)
METAVIR Score distribution	F4: 69.12% (47/68) F3: 16.18% (11/68) F2-F1: 11.76% (8/68) F0: 2.94% (2/68)	
Basal Viral Load (UI/mI)	<u><800.000</u> : 29.4% (20/68)	<u>>800.000</u> : 70.6% (48/68)
35		

Conclusions



The combination of simeprevir and sofosbuvir was effective in nonresponders and treatment-naive patients with chronic infection with hepatitis C virus genotype 1 and 4.

Poster number: <u>CP-101</u>

villalobostorresl@gmail.es